1. Generics Bulletin
  3. >>Earnings

A $10bn Target: Stelara Sales Break Barrier Ahead Of Biosimilar Launches

Ustekinumab Brand Grows By More Than A Tenth In Final Year Before Competition

 
• By Dave Wallace

With competition to Stelara due to kick in midway through 2024, the brand now represents a $10bn+ target for biosimilars, according to the latest figures from J&J.

Target growing from 2021 to 2023
Stelara represents a growing target for biosimilars • Source: Shutterstock

With the previous top-selling biologic, Humira (adalimumab), now facing widespread biosimilar competition, one of the next major brand targets on the horizon has notched up impressive sales in its final year before biosimilar competition starts to bite.

Stelara (ustekinumab) brought in $10.858bn for Johnson & Johnson in 2023, according to the latest figures reported by the originator, with this total up 11.7% over 2022’s $9.723bn. In the US, sales grew by 9% to $6

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

More from Business

UK-India FTA Could Offer ‘Significant Benefits’ For Generics And Biosimilars

 
• By Dave Wallace

A free trade agreement struck between the UK and India could over “significant benefits for the generic and biosimilar sectors,” Medicines UK believes. The off-patent industry association has also suggested further avenues for collaboration between the two governments on regulatory pathways and supply security.

Teva’s Uzedy Continues Surge As Olanzapine LAI Filing Nudges Closer

 
• By Dean Rudge

Teva underlined that it was “very pleased with this franchise we’re building and what we’ll bring to the care of patients with schizophrenia,” as it looks ahead to filing its olanzapine new drug application in the second half of 2025.

Dr Reddy’s Gears For Tariffs Scenario To Ensure No US Supply Disruption

 
• By Anju Ghangurde

Dr. Reddy's Laboratories preps for potential US tariffs, focusing on sustaining product supply and collaborating with customers on inventories. A recent US plant sale, the firm stressed, was unrelated to tariffs and underlines its openness to ‘make in the US’, where it launched 18 products in fiscal 2025.